ARS Pharmaceuticals (SPRY) announced a licensing agreement with ALK-Abello A/S (AKBLF), that provides ALK exclusive rights to commercialize ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and ...

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could lend it ...

Experts tell Al Jazeera to expect pressure to buy more US weapons, a trade dispute, and possibly a trade war.

The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...

Canada's main stock index edged higher on Monday as investors remained bullish following the U.S. presidential election, but gains were held in check by a sharp decline in gold mining shares. The ...

The newly approved vaccine, known as Arexvy, represents an advance in preventive health measures, addressing a significant adult demographic at risk from RSV complications. With this approval, Canada ...

Join the official fan community. Be the first to receive latest news, offers and more!

Teva Pharmaceutical Industries Ltd. ADR-2.23% $19.91B ...

And to review, we now have three RSV vaccines that are FDA approved for adults, two protein subunit RSV vaccines, one by Pfizer called ABRYSVO that does not contain an adjuvant, and one by GSK called ...

IPC Indice de Precios Y Cotizaciones 51,449.43-395.74-0.76% ...